EA028340B1 - Лечение и профилактика инфекций, вызываемых helicobacter pylori у людей и животных, с помощью композиции, содержащей высушенные распылением клетки лактобактерий - Google Patents
Лечение и профилактика инфекций, вызываемых helicobacter pylori у людей и животных, с помощью композиции, содержащей высушенные распылением клетки лактобактерий Download PDFInfo
- Publication number
- EA028340B1 EA028340B1 EA201391823A EA201391823A EA028340B1 EA 028340 B1 EA028340 B1 EA 028340B1 EA 201391823 A EA201391823 A EA 201391823A EA 201391823 A EA201391823 A EA 201391823A EA 028340 B1 EA028340 B1 EA 028340B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cells
- spray
- lactobacillus cells
- dried
- lactobacillus
- Prior art date
Links
- 241000186660 Lactobacillus Species 0.000 title claims abstract description 153
- 229940039696 lactobacillus Drugs 0.000 title claims abstract description 110
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 238000011282 treatment Methods 0.000 title claims abstract description 14
- 241001465754 Metazoa Species 0.000 title claims abstract description 11
- 238000011321 prophylaxis Methods 0.000 title claims abstract description 5
- 208000015181 infectious disease Diseases 0.000 title claims description 18
- 241000590002 Helicobacter pylori Species 0.000 title 1
- 229940037467 helicobacter pylori Drugs 0.000 title 1
- 239000007921 spray Substances 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 19
- 230000002496 gastric effect Effects 0.000 claims description 16
- 235000007882 dietary composition Nutrition 0.000 claims description 15
- 210000002784 stomach Anatomy 0.000 claims description 15
- 210000001015 abdomen Anatomy 0.000 claims description 11
- 235000015872 dietary supplement Nutrition 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 201000006549 dyspepsia Diseases 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 208000007882 Gastritis Diseases 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 8
- 208000002193 Pain Diseases 0.000 claims description 6
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 230000008029 eradication Effects 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 201000005917 gastric ulcer Diseases 0.000 claims description 4
- 208000004998 Abdominal Pain Diseases 0.000 claims description 3
- 206010000060 Abdominal distension Diseases 0.000 claims description 3
- 206010000087 Abdominal pain upper Diseases 0.000 claims description 3
- 206010006784 Burning sensation Diseases 0.000 claims description 3
- 206010061958 Food Intolerance Diseases 0.000 claims description 3
- 206010017886 Gastroduodenal ulcer Diseases 0.000 claims description 3
- 206010025476 Malabsorption Diseases 0.000 claims description 3
- 208000004155 Malabsorption Syndromes Diseases 0.000 claims description 3
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 3
- 208000025865 Ulcer Diseases 0.000 claims description 3
- 206010047700 Vomiting Diseases 0.000 claims description 3
- 230000004596 appetite loss Effects 0.000 claims description 3
- 208000024330 bloating Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 claims description 3
- 208000024798 heartburn Diseases 0.000 claims description 3
- 208000019017 loss of appetite Diseases 0.000 claims description 3
- 235000021266 loss of appetite Nutrition 0.000 claims description 3
- 206010025482 malaise Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 231100000397 ulcer Toxicity 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 230000001788 irregular Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 241000218033 Hibiscus Species 0.000 claims 1
- 235000005206 Hibiscus Nutrition 0.000 claims 1
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 238000010410 dusting Methods 0.000 claims 1
- 201000000498 stomach carcinoma Diseases 0.000 claims 1
- 206010019375 Helicobacter infections Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 168
- 244000005700 microbiome Species 0.000 description 18
- 238000004220 aggregation Methods 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 238000001694 spray drying Methods 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 241000207062 Candidatus Hepatobacter Species 0.000 description 7
- 230000002776 aggregation Effects 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 230000003278 mimic effect Effects 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 238000005507 spraying Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000006166 lysate Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000006041 probiotic Substances 0.000 description 6
- 235000018291 probiotics Nutrition 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 230000000529 probiotic effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000057297 Pepsin A Human genes 0.000 description 4
- 108090000284 Pepsin A Proteins 0.000 description 4
- 230000028654 Type IV pili-dependent aggregation Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 210000004051 gastric juice Anatomy 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- 229940111202 pepsin Drugs 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102100038776 ADP-ribosylation factor-related protein 1 Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000809413 Homo sapiens ADP-ribosylation factor-related protein 1 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 108010046334 Urease Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000005189 flocculation Methods 0.000 description 2
- 230000016615 flocculation Effects 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004265 EU approved glazing agent Substances 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000012182 cereal bars Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- -1 for example Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11169137A EP2532354A1 (de) | 2011-06-08 | 2011-06-08 | Sprühgetrocknete Lactobacillus Stämme / Zellen und deren Verwendung gegen Helicobacter Pylori |
| EP11185851 | 2011-10-19 | ||
| PCT/EP2012/060948 WO2012168468A1 (de) | 2011-06-08 | 2012-06-08 | Sprühgetrocknete lactobacillus stämme / zellen und deren verwendung gegen helicobacter pylori |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201391823A1 EA201391823A1 (ru) | 2014-04-30 |
| EA028340B1 true EA028340B1 (ru) | 2017-11-30 |
Family
ID=46489179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201391823A EA028340B1 (ru) | 2011-06-08 | 2012-06-08 | Лечение и профилактика инфекций, вызываемых helicobacter pylori у людей и животных, с помощью композиции, содержащей высушенные распылением клетки лактобактерий |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20140147427A1 (https=) |
| EP (1) | EP2717890B1 (https=) |
| JP (1) | JP6062931B2 (https=) |
| CN (1) | CN103648511B (https=) |
| BR (1) | BR112013031325A2 (https=) |
| EA (1) | EA028340B1 (https=) |
| ES (1) | ES2600963T3 (https=) |
| MX (1) | MX354047B (https=) |
| PL (1) | PL2717890T3 (https=) |
| WO (1) | WO2012168468A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150374764A1 (en) * | 2013-02-07 | 2015-12-31 | Organobalance Gmbh | Composition comprising lactobacillus and a carrier |
| DE102014103832A1 (de) | 2014-02-13 | 2015-08-13 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Zusammensetzung zur Behandlung von Magenbeschwerden |
| WO2016085932A1 (en) * | 2014-11-24 | 2016-06-02 | Nutrition Physiology Company, Llc | Lactic acid bacterium as pet dietary supplement |
| JP2016150904A (ja) * | 2015-02-16 | 2016-08-22 | サントリーホールディングス株式会社 | 抗腫瘍剤 |
| JP6339526B2 (ja) * | 2015-05-22 | 2018-06-06 | アサヒグループホールディングス株式会社 | 筋肉の分解抑制剤 |
| CN105132329B (zh) * | 2015-09-14 | 2019-04-16 | 西南民族大学 | 一种可预防胃溃疡的发酵乳杆菌Lactobacillus fermentum strain Lee及其保健用途 |
| GB2544481B (en) * | 2015-11-16 | 2019-12-11 | Century International Enterprises Ltd | A wearable article and a method for producing a wearable article |
| WO2017221799A1 (ja) * | 2016-06-20 | 2017-12-28 | 株式会社明治 | 上部消化管内菌叢改善剤 |
| KR101873899B1 (ko) * | 2016-08-09 | 2018-07-03 | 씨제이제일제당(주) | 락토바실러스 살리바리우스 cjls1511, 상기 균 또는 이의 사균체를 포함하는 동물 사료 첨가제 조성물, 및 상기 사균체의 제조 방법 |
| AU2018251616B2 (en) * | 2017-04-11 | 2025-04-03 | Servatus Ltd | Methods for the treatment of inflammation and inflammatory conditions |
| CN107361232A (zh) * | 2017-06-21 | 2017-11-21 | 安徽和盛伟业饲料有限公司 | 一种防治仔鸡冬季腹泻的饲料 |
| CN108403725B (zh) * | 2018-05-22 | 2021-02-09 | 浙江海正药业股份有限公司 | 用于治疗消化道溃疡的组合物及其应用 |
| US11617772B2 (en) * | 2018-09-11 | 2023-04-04 | Direct Digital Llc | Nutritional supplements and therapeutic compositions comprising probiotics |
| EP3870197A1 (en) * | 2018-10-24 | 2021-09-01 | Novozymes A/S | Probiotic supplement for metabolic health comprising lactobacillus |
| WO2021099655A1 (es) * | 2019-11-19 | 2021-05-27 | Inbiolev, S.L. | Procedimiento para el tratamiento de mostos y vinos y producto para la puesta en práctica del mismo |
| CN111357841A (zh) * | 2020-03-26 | 2020-07-03 | 湖南营养树生物科技有限公司 | 一种抗幽门螺旋杆菌的益生菌白茶的制备方法 |
| CN111548970B (zh) * | 2020-05-29 | 2021-03-26 | 江南大学 | 一株能够预防和/或治疗幽门螺杆菌感染的卷曲乳杆菌 |
| CN111471626A (zh) * | 2020-05-29 | 2020-07-31 | 江南大学 | 一株能够抑制幽门螺杆菌的瑞士乳杆菌及其应用 |
| CN111632084B (zh) * | 2020-06-22 | 2024-04-26 | 上海利康精准医疗技术有限公司 | 一种抑制幽门螺旋杆菌的复合益生菌组合物及其应用 |
| CN112314951A (zh) * | 2020-12-04 | 2021-02-05 | 王立强 | 一种可抗幽门螺杆菌的组合物及其制备方法 |
| CN114561313B (zh) * | 2021-08-26 | 2022-09-13 | 佛山市孛特碧欧微生物科技有限公司 | 格氏乳杆菌及其应用 |
| CN116004456B (zh) * | 2022-12-27 | 2023-10-27 | 广西爱生生命科技有限公司 | 一株抑制幽门螺旋杆菌感染的罗伊氏乳杆菌a21325及其应用 |
| WO2024252018A1 (en) * | 2023-06-08 | 2024-12-12 | Dsm Ip Assets B.V. | Novel process for producing lactobacillus rhamnosus |
| GB2634493A (en) * | 2023-09-05 | 2025-04-16 | Lant Medical Ltd | Veterinary non-antibiotic antimicrobial compositions |
| WO2025132761A1 (en) | 2023-12-22 | 2025-06-26 | Novozymes A/S | Producing a lactobacillus strain |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1112692A1 (en) * | 1999-06-24 | 2001-07-04 | Meiji Milk Products Company Limited | Drinks and foods capable of eliminating i helicobacter pylori /i |
| WO2007073709A1 (de) * | 2005-12-22 | 2007-07-05 | Organobalance Gmbh | Neue lactobacillus stämme und deren verwendung gegen helicobacter pylori |
| WO2008039531A1 (en) * | 2006-09-27 | 2008-04-03 | Little Calumet Holdings, Llc | Probiotic oral dosage forms |
| WO2008060198A1 (en) * | 2006-11-17 | 2008-05-22 | Sca Hygiene Products Ab | Lactobacillus fermentum ess-1, dsm17851 and its use for the treatment and/or prevention of candidiasis and urinary tracrinfections |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3897307A (en) * | 1974-10-23 | 1975-07-29 | Hansens Lab Inc | Stabilized dry cultures of lactic acid-producing bacteria |
| DE3135329A1 (de) | 1981-09-05 | 1983-03-24 | Basf Ag, 6700 Ludwigshafen | Verfahren zur herstellung von trockenpulvern oxidationsempfindlicher substanzen |
| EP0285682B2 (en) | 1987-04-06 | 1997-08-06 | F. Hoffmann-La Roche Ag | Process for the manufacture of vitamin preparations |
| US5716615A (en) * | 1992-02-10 | 1998-02-10 | Renata Maria Anna Cavaliere Vesely | Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use |
| JP4509250B2 (ja) * | 1999-06-24 | 2010-07-21 | 明治乳業株式会社 | Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉ除菌性医薬品 |
| FR2801316B1 (fr) * | 1999-11-18 | 2005-03-25 | Rhodia Food | Procede de sechage des bacteries |
| JP3363438B2 (ja) * | 2000-05-02 | 2003-01-08 | ビオフェルミン製薬株式会社 | 噴霧乾燥による菌体乾燥物 |
| EE04580B1 (et) * | 2001-06-29 | 2006-02-15 | Tartu �likool | Mikroorganismi tüvi Lactobacillus fermentum ME-3 kui antimikroobne ja antioksüdantne probiootikum |
| US7101565B2 (en) * | 2002-02-05 | 2006-09-05 | Corpak Medsystems, Inc. | Probiotic/prebiotic composition and delivery method |
| DE60238663D1 (de) * | 2002-04-05 | 2011-02-03 | Nestle Sa | Zusammensetzungen und Verfahren zur Verbesserung von Lipidassimilation in Haustieren |
| WO2004087891A1 (en) * | 2003-04-02 | 2004-10-14 | Axcan Pharma S.A. | Lactobacillus fermentum strain and uses thereof |
| DK3067057T3 (da) * | 2005-09-28 | 2023-02-13 | Nordic Rebalance As | Probiotisk fermenteret cerealiesammensætninger til anvendelse ved behandling af gastrointestinale lidelser forårsaget af pro-inflammatoriske bakterier |
| ES2578261T3 (es) * | 2007-05-18 | 2016-07-22 | Nestec S.A. | Lactobacillus johnsonii para prevenir infecciones postoperatorias |
| EA020627B1 (ru) * | 2008-06-26 | 2014-12-30 | Синва Фармасьютикал Ко., Лтд. | Способ получения клеток наноразмерных молочно-кислых бактерий и композиции на их основе |
-
2012
- 2012-06-08 EP EP12733436.5A patent/EP2717890B1/de active Active
- 2012-06-08 US US14/124,535 patent/US20140147427A1/en active Pending
- 2012-06-08 ES ES12733436.5T patent/ES2600963T3/es active Active
- 2012-06-08 PL PL12733436T patent/PL2717890T3/pl unknown
- 2012-06-08 JP JP2014514099A patent/JP6062931B2/ja active Active
- 2012-06-08 EA EA201391823A patent/EA028340B1/ru unknown
- 2012-06-08 WO PCT/EP2012/060948 patent/WO2012168468A1/de not_active Ceased
- 2012-06-08 BR BR112013031325A patent/BR112013031325A2/pt not_active Application Discontinuation
- 2012-06-08 MX MX2013014340A patent/MX354047B/es active IP Right Grant
- 2012-06-08 CN CN201280033643.5A patent/CN103648511B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1112692A1 (en) * | 1999-06-24 | 2001-07-04 | Meiji Milk Products Company Limited | Drinks and foods capable of eliminating i helicobacter pylori /i |
| WO2007073709A1 (de) * | 2005-12-22 | 2007-07-05 | Organobalance Gmbh | Neue lactobacillus stämme und deren verwendung gegen helicobacter pylori |
| WO2008039531A1 (en) * | 2006-09-27 | 2008-04-03 | Little Calumet Holdings, Llc | Probiotic oral dosage forms |
| WO2008060198A1 (en) * | 2006-11-17 | 2008-05-22 | Sca Hygiene Products Ab | Lactobacillus fermentum ess-1, dsm17851 and its use for the treatment and/or prevention of candidiasis and urinary tracrinfections |
Non-Patent Citations (5)
| Title |
|---|
| LORCA GRACIELA L. ET AL.: "Lactobacillus acidophilus autolysins inhibit helicobacter pylori in vitro", CURRENT MICROBIOLOGY, SPRINGER, BOSTON, vol. 42, 1 January 2001 (2001-01-01), Boston, pages 39 - 44, XP002970548, ISSN: 0343-8651, DOI: 10.1007/s002840010175 * |
| NAOMI UEMURA, SHIRO OKAMOTO, SOICHIRO YAMAMOTO, NOBUTOSHI MATSUMURA, SHUJI YAMAGUCHI, MICHIO YAMAKIDO, KIYOMI TANIYAMA, NAOMI SASA: "Helicobacter pylori Infection and the Development of Gastric Cancer", NEW ENGLAND JOURNAL OF MEDICINE, NEW ENGLAND JOURNAL OF MEDICINE, vol. 345, no. 11, 13 September 2001 (2001-09-13), pages 784 - 789, XP055037354, ISSN: 00284793, DOI: 10.1056/NEJMoa001999 * |
| SERVIN, A.L.: "Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens", FEMS MICROBIOLOGY REVIEWS, ELSEVIER, AMSTERDAM; NL, vol. 28, no. 4, 1 October 2004 (2004-10-01), AMSTERDAM; NL, pages 405 - 440, XP004564881, ISSN: 0168-6445 * |
| SOBALA G M, ET AL: "Acute Helicobacter pylori infection: clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations.", GUT, BRITISH MEDICAL ASSOCIATION, LONDON,, UK, vol. 32, no. 11, 1 November 1991 (1991-11-01), UK, pages 1415 - 1418, XP002682923, ISSN: 0017-5749, DOI: 10.1136/gut.32.11.1415 * |
| TO B. C. S., ETZEL M. R.: "SPRAY DRYING, FREEZE DRYING, OR FREEZING OF THREE DIFFERENT LACTIC ACID BACTERIA SPECIES.", JOURNAL OF FOOD SCIENCE, WILEY-BLACKWELL PUBLISHING, INC., US, vol. 62., no. 03., 1 January 1997 (1997-01-01), US, pages 576 - 578 + 585., XP002038914, ISSN: 0022-1147, DOI: 10.1111/j.1365-2621.1997.tb04434.x * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103648511B (zh) | 2018-12-07 |
| MX354047B (es) | 2018-02-09 |
| BR112013031325A2 (pt) | 2017-06-06 |
| JP6062931B2 (ja) | 2017-01-18 |
| ES2600963T3 (es) | 2017-02-13 |
| EP2717890A1 (de) | 2014-04-16 |
| EA201391823A1 (ru) | 2014-04-30 |
| WO2012168468A1 (de) | 2012-12-13 |
| PL2717890T3 (pl) | 2017-12-29 |
| JP2014518897A (ja) | 2014-08-07 |
| MX2013014340A (es) | 2014-07-09 |
| CN103648511A (zh) | 2014-03-19 |
| US20140147427A1 (en) | 2014-05-29 |
| EP2717890B1 (de) | 2016-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA028340B1 (ru) | Лечение и профилактика инфекций, вызываемых helicobacter pylori у людей и животных, с помощью композиции, содержащей высушенные распылением клетки лактобактерий | |
| RU2466185C2 (ru) | ПРОБИОТИЧЕСКИЙ ШТАММ Bifidobacterium longum, ПРОБИОТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЯ ШТАММА Bifidobacterium longum | |
| US7846711B2 (en) | Lactobacillus strains and uses thereof | |
| ES2451618T3 (es) | Matriz de proteína maleable y usos de estas | |
| US20080102061A1 (en) | Use hydrolyzed medium containing microorganisms medicinally | |
| JPH0656680A (ja) | 凍結乾燥された乳酸菌を含有する栄養学的及び／又は薬学的組成物、それらの調製及び使用 | |
| US11376289B2 (en) | Composition and uses thereof | |
| TWI689585B (zh) | 新穎乳酸菌株及包含新穎乳酸菌株之免疫賦活劑 | |
| CN118843685A (zh) | 新的益生菌及其用途 | |
| KR102084350B1 (ko) | 용암해수 미네랄 코팅 프로바이오틱스의 제조방법 및 이를 이용한 용암해수 미네랄 코팅 프로바이오틱스 | |
| CN111011856A (zh) | 用于缓解胃病的组合物、其制备方法及用于缓解胃病的食品 | |
| CN116942706A (zh) | Akkermansia muciniphila在制备预防、治疗和/或辅助治疗肠炎的产品中的应用 | |
| KR20150087634A (ko) | 여드름 원인균 프로피오니박테리움 아크네스의 생장억제 효능을 가지는 락토바실러스 파라카제이 hy7301 및 이를 유효성분으로 함유하는 제품 | |
| CN119174784A (zh) | 动物双歧杆菌乳亚种或组合物在制备用于预防和/或治疗代谢性疾病的产品中的应用 | |
| TW201902499A (zh) | 用於類鐸受體２活性化之組成物 | |
| AU2011212513B2 (en) | Improvement of immunomodulatory properties of Lactobacillus strains | |
| JP5209294B2 (ja) | インターロイキン１２産生促進剤 | |
| KR102617297B1 (ko) | 클로스트리디움 디피실리 감염의 치료 또는 예방용 조성물 | |
| JP6671950B2 (ja) | 機能性胃腸症改善剤 | |
| KR102246957B1 (ko) | 장내 세균총에 유익한 효능을 가진 유산균을 활용한 면역력 향상 기능성 첨가물 및 그 제조방법 | |
| KR20230138497A (ko) | 관절 기능 개선용 조성물 | |
| WO2025132761A1 (en) | Producing a lactobacillus strain | |
| RU2264451C2 (ru) | Биопрепарат "бифистим от 3 месяцев до 3 лет" для профилактики и лечения дисбактериозов и инфекционнных болезней желудочно-кишечного тракта у детей в возрасте от 3 месяцев до 3 лет, биологически активная добавка к пище "бифистим от 3 месяцев до 3 лет" для профилактики дисбактериозов и восстановления микрофлоры желудочно-кишечного тракта после антибиотикотерапии и других неблагоприятных воздействий у детей в возрасте от 3 месяцев до 3 лет и консорциум бифидобактерий для коррекции микрофлоры желудочно-кишечного тракта у детей в возрасте от 3 месяцев до 3 лет | |
| JP2011057622A (ja) | ラクトバチルス・プランタラムの菌体又は培養物を有効成分とするインスリン抵抗性改善剤 | |
| WO2026038968A1 (en) | Lactobacillus helveticus bgra43 strain for the treatment of liver steatosis |